ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation

Andrew Z. Wang, Kai Yuet, Liangfang Zhang, Frank X. Gu, Minh Huynh-Le, Aleksandar F. Radovic-Moreno, Philip W. Kantoff, Neil H. Bander, Robert Langer, Omid C. Farokhzad

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Abstract

Aim: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. Method: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. Results: Using docetaxel, indium111 and yttrium90 as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. Conclusion: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalNanomedicine
Volume5
Issue number3
DOIs
StatePublished - Apr 2010
Externally publishedYes

Keywords

  • Biologically targeted nanoparticle
  • ChemoRad NP
  • Chemoradiation
  • Chemoradiation nanoparticle
  • Nanomedicine
  • Nanotechnology
  • Prostate cancer

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint

Dive into the research topics of 'ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation'. Together they form a unique fingerprint.

Cite this